Published Clinical research
Ayahuasca
Ayahuasca is a sacred plant teacher from the Amazon with benefits for PTSD, anxiety, depression, addiction, and spiritual growth.
July 16, 2021
Frontiers in Psychiatry
Cross-Sectional Associations Between Lifetime Use of Psychedelic Drugs and Psychometric Measures During the COVID-19 Confinement: A Transcultural Study
July 13, 2021
Scientific Reports
Associations between lifetime classic psychedelic use and cardiometabolic diseases
June 9, 2021
Frontiers in Psychiatry
Ceremonial Ayahuasca in Amazonian Retreats—Mental Health and Epigenetic Outcomes From a Six-Month Naturalistic Study
May 5, 2021
Frontiers in Pharmacology
The Shipibo Ceremonial Use of Ayahuasca to Promote Well-Being: An Observational Study
April 12, 2021
Frontiers in Pharmacology
Influence of Context and Setting on the Mental Health and Wellbeing Outcomes of Ayahuasca Drinkers: Results of a Large International Survey
March 25, 2021
Frontiers in Pharmacology
Psychedelic Communitas: Intersubjective Experience During Psychedelic Group Sessions Predicts Enduring Changes in Psychological Wellbeing and Social Connectedness
April 23, 2019
PLoS One
Survey of subjective “God encounter experiences”: Comparisons among naturally occurring experiences and those occasioned by the classic psychedelics psilocybin, LSD, ayahuasca, or DMT
June 15, 2018
Psychological Medicine
Rapid antidepressant effects of the psychedelic ayahuasca in treatment-resistant depression: a randomized placebo-controlled trial
May 8, 2018
Frontiers in Psychiatry
Cortisol Modulation by Ayahuasca in Patients With Treatment Resistant Depression and Healthy Controls
April 24, 2018
Frontiers in Psychiatry
Assessment of Alcohol and Tobacco Use Disorders Among Religious Users of Ayahuasca
March 20, 2018
Frontiers in Pharmacology
Four Weekly Ayahuasca Sessions Lead to Increases in “Acceptance” Capacities: A Comparison Study With a Standard 8-Week Mindfulness Training Program
February 10, 2010
Journal of Ethnopharmacology
Banisteriopsis caapi, a unique combination of MAO inhibitory and antioxidative constituents for the activities relevant to neurodegenerative disorders and Parkinson’s disease
January, 2007
Addiction
Risk assessment of ritual use of oral dimethyltryptamine (DMT) and harmala alkaloids